CAR T-cell treatment targeting CD19 [13] and CD20 has shown great potential in the therapy of malignant tumors of the B-cell type; acute lymphocytic leukemia (ALL) is one example [14,15], as is non-Hodgkin lymphoma (NHL) [14]. The gene discussed is CD19; the disease is non-Hodgkin lymphoma.